drugset / Trial / NCT02911350

Safety Study of Combination of Hormone Therapy, Paclitaxel and Radiation Therapy to Treat Prostate Cancer

NCT02911350

Phase 1 Completed 23 enrolled NYU Langone Health
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if the combination therapy of Hormone, Paclitaxel and Radiation therapy are effective in treatment of locally advanced prostate cancer

Timeline

Start
2000-05
Primary completion
2016-12
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Bicalutamide Other / unclassified
Subject Goserelin Other / unclassified
Subject Leuprolide Other / unclassified
Subject Paclitaxel Small molecule 30 mg/m2 Intravenous
Subject Paclitaxel Small molecule 35 mg/m2 Intravenous
Subject Paclitaxel Small molecule 40 mg/m2 Intravenous
Subject Paclitaxel Small molecule 45 mg/m2 Intravenous
Subject flutamide Small molecule

Indications